| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Candida albicans |
| species reactivity | Candida |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available size | 1 mg |
Candida albicans Antigen BA117VS
$648.00
Summary
- Virion/Serion Immunologics Antigen for research use (RUO)
- Candida albicans Antigen, recombinant
- Suitable for detection of IgA, IgG & IgM antibodies in ELISA
- Lot specific concentration, specified in mg/mL
- 1 mg
Available on backorder
Candida albicans Antigen BA117VS
| kit |
|---|
| Research area Infectious Disease |
| Storage Store at -65°C or lower. Avoid repeated freeze-thaw cycles. Sonicate before use. 10 years from date of manufacture (under recommended storage conditions). |
| Form liquid |
| Associated products Candida albicans Antigen (BA117VS) Candida Antigen Assay Control (BC200) Candida albicans IgA Control Serum (BC117A) Candida albicans IgG Control Serum (BC117G) Candida albicans IgM Control Serum (BC117M) Candida albicans IgA ELISA Kit (ESR117A) Candida albicans IgG ELISA Kit (ESR117G) Candida albicans IgM ELISA Kit (ESR117M) Candida Antigen Detection ELISA Kit (ESR200) |
| target relevance |
|---|
| Organism Candida albicans |
| Structure and strains Candida albicans is an opportunistic pathogenic yeast that is a common member of the human gut flora. It can also survive outside the human body. It is detected in the gastrointestinal tract and mouth in 40 60% of healthy adults. It is usually a commensal organism, but it can become pathogenic in immunocompromised individuals under a variety of conditions. It is one of the few species of the genus Candida that cause the human infection candidiasis, which results from an overgrowth of the fungus. Candidiasis is, for example, often observed in HIV-infected patients. C. albicans is the most common fungal species isolated from biofilms either formed on (permanent) implanted medical devices or on human tissue. C. albicans, C. tropicalis, C. parapsilosis, and C. glabrata are together responsible for 50 90% of all cases of candidiasis in humans. A mortality rate of 40% has been reported for patients with systemic candidiasis due to C. albicans. By one estimate, invasive candidiasis contracted in a hospital causes 2,800 to 11,200 deaths yearly in the US. Nevertheless, these numbers may not truly reflect the true extent of damage this organism causes, given new studies indicating that C. albicans can cross the blood brain barrier in mice. |
| Disease Pathogens Candida albicans is an ubiquitous yeast which, like all Candida spp., belongs to the family of yeast-like fungi. Apart from the yeast form, which primarily causes superficial infections, socalled pseudo mycelia are a further morphologic manifestation of the pathogen. Germ tubes and the development of pseudomycelia mainly occur in cases of systemic mycosis. Candida spp. produce and excrete a range of destructive enzymes, that enable the facultative pathogenic microorganisms to penetrate mucous membrane barriers and blood vessels. In general, Candida spp. are transmitted from person to person by smear contamination. The primary entry site is the oral cavity. Changes in the fungistatic properties of the skin, which are a consequence of a slightly acidic pH value and the antagonistic bacterial flora, can facilitate the establishment of superficial candidiasis of the skin surface. Systemic mycosis results from colonization of mucous membranes, particularly in the gastrointestinal tract. |
| Detection and diagnosis The diagnosis of candidiasis on the basis of serological methods is not easy: On the one hand transient yeast colonization may induce an antibody response, on the other hand systemic Candida mycosis in immunosuppressed patients may only lead to minor changes in antibody activities. Such situations make critical interpretation of serological findings necessary. In addition, systemic Candida infections may not cause typical symptoms. Currently, no single technique in isolation allows for a definitive serological diagnosis of candidiasis. Surveillance of at risk patients and therapy control requires the use of a variety of methods including serology and antigen detection |
Data
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.| pmid | title | authors | citation |
|---|
Protocols
| relevant to this product |
|---|
| BA117VS protocol |
Documents
| Product data sheet |
|---|
| BA117VS |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.